144506-14-9

Basic information

• Product Name: LICOCHALCONEC
• Synonyms: LICOCHALCONEC;4,4'-Dihydroxy-2-Methoxy-3-prenylchalcone;2-Propen-1-one,3-[4-hydroxy-2-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-1-(4-hydroxyphenyl)-,(2E)-
• CAS NO: 144506-14-9
• Molecular Formula: C21H22O4
• Molecular Weight: 338.39698
• Product Categories: sy;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Chalcones
• Mol File: 144506-14-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 536.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.181±0.06 g/cm3 (20 ºC 760 Torr)
• PKA: 7.82±0.15(Predicted)
• CAS DataBase Reference: LICOCHALCONEC(CAS DataBase Reference)
• NIST Chemistry Reference: LICOCHALCONEC(144506-14-9)
• EPA Substance Registry System: LICOCHALCONEC(144506-14-9)

Safety Data

• Hazardous Substances Data: 144506-14-9(Hazardous Substances Data)

Usage

General Description

Licochalcone C is a natural phenolic compound found in the root of Chinese licorice plant. It is known for its antioxidant, anti-inflammatory, and anti-cancer properties. Licochalcone C has been shown to inhibit the growth of various cancer cells, including breast, prostate, and colon cancer. It also has potential in preventing and treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, licochalcone C has been researched for its potential in treating skin disorders, such as acne and atopic dermatitis, due to its anti-inflammatory and antimicrobial effects. Overall, licochalcone C has shown promise as a natural compound with various health benefits.

Upstream product

• 163041-67-6 2-hydroxy-3-(3-methylbut-2-en-1-yl)-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzaldehyde 
• 870-63-3 prenyl bromide 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 32268-30-7 2,4-dihydroxy-3-(3-methyl-2-but-en-1-yl)benzaldehyde 
• 1449372-41-1 C₁₅H₂₀O₄ 
• 99-93-4 4-Hydroxyacetophenone 
• 1449372-40-0 C₁₄H₁₈O₄ 
• 115-18-4 2-methyl-3-buten-2-ol 

Relevant articles and documents

Microbial conjugation studies of licochalcones and xanthohumol

Microbial conjugation studies of licochalcones (1–4) and xanthohumol (5) were performed by using the fungi Mucor hiemalis and Absidia coerulea. As a result, one new glucosylated metabolite was produced by M. hiemalis whereas four new and three known sulfated metabolites were obtained by transformation with A. coerulea. Chemical structures of all the metabolites were elucidated on the basis of 1D-, 2D-NMR and mass spectroscopic data analyses. These results could contribute to a better understanding of the metabolic fates of licochalcones and xanthohumol in mammalian systems. Although licochalcone A 4′-sulfate (7) showed less cytotoxic activity against human cancer cell lines compared to its substrate licochalcone A, its activity was fairly retained with the IC50 values in the range of 27.35–43.07 μM.

Facile synthesis of licochalcone C

Licochalcone C was synthesized from commercially available 2,4-dihydroxybenzaldehde by using regioselective Al2O 3-mediated C-prenylation followed by conventional Claisen-Schmidt condensation in basic condition.

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.